Preoperative oxaliplatin, capecitabine, and external beam radiotherapy in patients with newly diagnosed, primary operable, cT3NxMo, low rectal cancer: A phase II study

Strahlentherapie und Onkologie

Volumn 187, Issue 2, 2011, Pages 100-107

  Öfner, Dietmar ^a,b   DeVries, Alexander F ^c   Schaberl Moser, Renate ^d   Greil, Richard ^a   Rabl, Hans ^e   Tschmelitsch, Jörg ^f   Zitt, Matthias ^b   Kapp, Karin S ^d   Fastner, Gerd ^a   Keil, Felix ^e   Eisterer, Wolfgang ^b   Jäger, Robert ^b   Offner, Felix ^c   Gnant, Michael ^g   Thaler, Josef ^h  

^a PARACELSUS MEDICAL UNIVERSITY   (Austria)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c Hospital Feldkirch   (Austria)

^d MEDICAL UNIVERSITY OF GRAZ   (Austria)

^e Landeskrankenhaus Leoben Eisenerz   (Austria)

^f St Veit Hospital   (Austria)

^g MEDICAL UNIVERSITY OF VIENNA   (Austria)

^h Clinical Centre Wels Grieskirchen   (Austria)

Author keywords

Capecitabine; Chemoradiation; Oxaliplatin; Rectal cancer

Indexed keywords

CAPECITABINE; OXALIPLATIN; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; FLUOROURACIL; PLATINUM COMPLEX;

ADULT; AGED; ANEMIA; ARTICLE; BLEEDING; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CHEMOTHERAPY INDUCED EMESIS; CONSTIPATION; DIABETES MELLITUS; DIARRHEA; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; EXTERNAL BEAM RADIOTHERAPY; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HAND FOOT SYNDROME; HEMATOLOGIC DISEASE; HUMAN; HYPERTENSION; INFECTION; LEUKOPENIA; LIVER TOXICITY; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MOTOR NEUROPATHY; NAUSEA AND VOMITING; NEUROLOGICAL COMPLICATION; NEUROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 2 CLINICAL TRIAL; PREOPERATIVE TREATMENT; PSYCHOSIS; RADIATION DOSE; RADIATION SAFETY; RADIATION SICKNESS; RECTUM CANCER; SENSORY NEUROPATHY; SIDE EFFECT; SKIN TOXICITY; STOMATITIS; TREATMENT OUTCOME; TREATMENT PLANNING; TREATMENT RESPONSE; WEIGHT CHANGE; ADENOCARCINOMA; ADJUVANT THERAPY; CANCER INVASION; CLINICAL TRIAL; COMPUTER ASSISTED RADIOTHERAPY; DOSE RESPONSE; DRUG ADMINISTRATION; FEASIBILITY STUDY; INTRAVENOUS DRUG ADMINISTRATION; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; ORAL DRUG ADMINISTRATION; PATHOLOGY; RECTUM TUMOR;

ADENOCARCINOMA; ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEASIBILITY STUDIES; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; RADIOTHERAPY, CONFORMAL; RECTAL NEOPLASMS; TREATMENT OUTCOME;

EID: 79954476953     PISSN: 01797158     EISSN: 1439099X     Source Type: Journal    
DOI: 10.1007/s00066-010-2182-6     Document Type: Article

References (42)

1. Aschele C, Pinto C, Cordio S, et al. Preoperative fluorouracil (FU)-based chemoradiation with and without weekly oxaliplatin in locally advanced rectal cancer: Pathologic response analysis of the Studio Terapia Adiuvante Retto (STAR)-01 randomized phase III trial. J Clin Oncol 2009;27:18s.abstract CRA4008.
2. Beets-Tan RGH, Beets GL. Rectal cancer: review with emphasis on MR imaging. Radiology 2004;232:335-46. (Pubitemid 38971269)
3. Bosset JF, Magnin V, Maingon P, et al. Preoperative radiochemotherapy in rectal cancer: long-term results of a phase II trial. Int J Radiat Oncol Biol Phys 2000;46:323-7. (Pubitemid 30067781)
4. Bosset JF, Collette L, Calais G, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 2006;355:1114-23. (Pubitemid 44394918)
5. Bouzourene H, Bosman FT, Seelentag W, et al. Importance of tumor regression assessment in predicting the outcome in patients with locally advanced rectal carcinoma who are treated with preoperative radiotherapy. Cancer 2002;94:1121-30. (Pubitemid 34150868)
6. Dunst J, Reese T, Debus J, et al. Phase-II-study of preoperative chemoradiation with capecitabine in rectal cancer. J Clin Oncol 2004;22:14s.abstract 3559.
7. Dunst J, Debus J, Rudat V, et al. Neoadjuvant capecitabine combined with standard radiotherapy in patients with locally advanced rectal cancer: mature results of a phase II trial. Strahlenther Onkol 2008;184:450-6.
8. Francois Y, Nemoz CJ, Baulieux J, et al. Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer: the Lyon R90-01 randomized trial. J Clin Oncol 1999;17:2396.
9. García-Aguilar J, Hernandez de Anda E, et al. A pathologic complete response to preoperative chemoradiation is associated with lower local recurrence and improved survival in rectal cancer patients treated by mesorectal excision. Dis Colon Rectum 2003;46:298-304. (Pubitemid 36331646)
10. Gérard JP, Conroy T, Bonnetain F, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol 2006;24:4620-5. (Pubitemid 46630960)
11. Gérard J, Azria D, Gourgou-Bourgade S, et al. Randomized multicenter phase III trial comparing neoadjuvant RT-Capox and RT-Cap in patients (pts) with locally advanced rectal cancer: Preliminary safety results of the ACCORD 12/0405 PRODIGE-2. J Clin Oncol 2008;26:20s.abstract 4089.
12. Gérard J, Azria D, Gourgou-Bourgade S, et al. Comparison of two neoad- juvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2. J Clin Oncol 2010;28:1638-44.
13. Glynne-Jones R, Dunst J, Sebag-Montefiore D. The integration of oral capecitabine into chemoradiation regimens for locally advanced rectal cancer: how successful have we been? Ann Oncol 2006;17:361-71. (Pubitemid 43329571)
14. Glynne-Jones R, Sebag-Montefiore D, Maughan TS, et al. A phase I dose escalation study of continuous oral capecitabine in combination with oxaliplatin and pelvic radiation (XELOX-RT) in patients with locally advanced rectal cancer. Ann Oncol 2006;17:50-6. (Pubitemid 43033839)
15. Grann A, Feng C, Wong D, et al. Preoperative combined modality therapy for clinically resectable uT3 rectal adenocarcinoma. Int J Radiat Oncol Biol Phys 2001;49:987-95. (Pubitemid 32184605)
16. Guillem JG, Díaz-González JA, Minsky BD, et al. cT3N0 rectal cancer: potential overtreatment with preoperative chemoradiotherapy is warranted. J Clin Oncol 2008;26:368-73. (Pubitemid 351171686)
17. Hartley A, Ho KF, McConkey C, et al. Pathological complete response following pre-operative chemoradiotherapy in rectal cancer: analysis of phase II/ III trials. Br J Radiol 2005;78:934-8. (Pubitemid 41582245)
18. Heald RJ, Husband EM, Ryall RD. The mesorectum in rectal cancer surgery - the clue to pelvic recurrence? Br J Surg 1982;69:613-6. (Pubitemid 12038080)
19. Heald RJ, Moran BJ, Ryall RD, et al. Rectal cancer: the Basingstoke experience of total mesorectal excision, 1978-1997. Arch Surg 1998;133: 894-9. (Pubitemid 28374285)
20. Janjan NA, Abbruzzese J, Pazdur R, et al. Prognostic implications of response to preoperative infusional chemoradiation in locally advanced rectal cancer. Radiother Oncol 1999;51:153-60. (Pubitemid 29320309)
21. Kapiteijn E, Marijnen CA, Nagtegaal ID, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 2001;345:638-46.
22. Keilholz L, Mese M, Henneking K, et al. Effect of total mesorectal excision on the outcome of rectal cancer after standardized postoperative radiochemotherapy: do randomized studies translate into clinical routine? Strahlenther Onkol 2009;185:364-70.
23. Kim JC, Kim TW, Kim JH, et al. Preoperative concurrent radiotherapy with capecitabine before total mesorectal excision in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2005;63:346-53. (Pubitemid 41317150)
24. Kim JS, Kim JS, Cho MJ, et al. Comparison of the efficacy of oral capecitabine versus bolus 5-FU in preoperative radiotherapy of locally advanced rectal cancer. J Korean Med Sci 2006;21:52-7.
25. Lin EH, Skibber J, Delcos M, et al. A phase II study of capecitabine and concomitant boost radiotherapy (XRT) in patients (pts) with locally advanced rectal cancer (LARC). J Clin Oncol 2005;23:16s.abstract 3593.
26. Machiels JP, Duck L, Honhon B, et al. Phase II study of preoperative oxaliplatin, capecitabine and external beam radiotherapy in patients with rectal cancer: the RadiOxCape study. Ann Oncol 2005;16:1898-905. (Pubitemid 41724278)
27. Marquardt F, Rödel F, Capalbo G, et al. Molecular targeted treatment and radiation therapy for rectal cancer. Strahlenther Onkol 2009;185:371-8.
28. Miwa M, Ura M, Nishida M, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998;34:1274-81. (Pubitemid 28342121)
29. Mohiuddin M, Hayne M, Regine WF, et al. Prognostic significance of postchemoradiation stage following preoperative chemotherapy and radiation for advanced/recurrent rectal cancers. Int J Radiat Oncol Biol Phys 2000;48:1075-80.
30. De Paoli A, Chiara S, Luppi G, et al. Capecitabine in combination with preoperative radiation therapy in locally advanced, resectable, rectal cancer: a multicentric phase II study. Ann Oncol 2006;17:246-51. (Pubitemid 43160113)
31. Paskeviciute B, Bölling T, Brinkmann M, et al. Impact of (18)F-FDG-PET/CT on staging and irradiation of patients with locally advanced rectal cancer. Strahlenther Onkol 2009;185:260-5.
32. Rödel C, Grabenbauer GG, Papadopoulos T, et al. Phase I/II trial of capecitabine, oxaliplatin, and radiation for rectal cancer. J Clin Oncol 2003;21:3098-104. (Pubitemid 46613485)
33. Rödel C, Martus P, Papadoupolos T, et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 2005;23:8688-96. (Pubitemid 46211512)
34. Rödel C, Liersch T, Hermann RM, et al. Multicenter phase II trial of chemoradiation with oxaliplatin for rectal cancer. J Clin Oncol 2007;25:110-7. (Pubitemid 350003058)
35. Rödel C, Sauer R, Fietkau R. [The role of magnetic resonance imaging to select patients for preoperative treatment in rectal cancer]. Strahlenther Onkol 2009;185:488-92.
36. Rutten H, Sebag-Montefiore D, Glynne-Jones R, et al. Capecitabine, oxaliplatin, radiotherapy, and excision (CORE) in patients with MRI-defined locally advanced rectal adenocarcinoma: Results of an international multicenter phase II study. J Clin Oncol 2006;24:Abs 3528.
37. Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004;351:1731-40.
38. Sawada N, Ishikawa T, Sekiguchi F, et al. X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts. Clin Cancer Res 1999;5:2948-53. (Pubitemid 29493974)
39. Sefr R, Kocakowa I, Spelda S. Preoperative radiotherapy and oral capecitabine improve surgical results in patients with locally advanced mid-lower rectal cancer. Eur J Cancer 2005;3:2s.abstract 709.
40. Stelzmueller I, Zitt M, Aigner F, et al. Postoperative morbidity following chemoradiation for locally advanced low rectal cancer. J Gastrointest Surg 2009;13:657-67.
41. Theodoropoulos G, Wise WE, Padmanabhan A, et al. T-level downstaging and complete pathologic response after preoperative chemoradiation for advanced rectal cancer result in decreased recurrence and improved disease-free survival. Dis Colon Rectum 2002;45:895-903. (Pubitemid 34761469)
42. Valentini V, Coco C, Picciocchi A, et al. Does downstaging predict improved outcome after preoperative chemoradiation for extraperitoneal locally advanced rectal cancer? A long-term analysis of 165 patients. Int J Radiat Oncol Biol Phys 2002;53:664-74. (Pubitemid 34626505)